Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
•
Allergic Rhinitis and Conjunctivitis
Are there best practices for integrating pollen, wildfire smoke, and AQI data into asthma/allergic rhinitis action plans?
Related Questions
Is there a specific group of children that you start on AIT for prevention of asthma?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
How do you address the discrepancy between traditional allergy skin testing and the Rinkel skin test results?
Is there any genetic testing available for the CDHR3 receptor?
Do you consider the efficacy of different nasal sprays when prescribing for allergic rhinitis or conjunctivitis?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Should a patient on medium-dose ICS/LABA with normal PFTs, but who shows a greater than 10% decrease in FEV1 if their PFTs are done after 24 hours off their inhaler, be started on a biologic?
When initiating patients on Ragwitek, Odactra, and Grastek and the plan is to continue on all 3 tablets for the next 5 years instead of only for seasons, how far apart from each one do you give the initial dose?
Should thunderstorm asthma be incorporated into asthma action plans?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
